Sponsor: Cellectar Biosciences, Inc.
Sponsor Study ID: DCL-16-001
Study Title: An Open Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B Cell Malignancies (CLOVER 1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER WaM)
CTO #: 103410
NCT Number: NCT02952508
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: Part A of this study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of CLR 131 in patients with WM that have received at least two prior lines of therapy.